You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
These hybrid capture-based methods target gene transcripts of interest, which could shrink sequencing costs for some experiments by as much as 90 percent.
The synthetic biology firm had total revenues of $19.3 million and withdrew its financial guidance for fiscal year 2020 citing uncertainty caused by COVID-19.
A nationwide, multi-agency effort to sequence the virus causing COVID-19 is a logistical nightmare, but experts say the UK is well situated to succeed.
The UK's Biosearch Technologies will distribute Arbor Biosciences' myBaits custom, targeted NGS panels to agricultural and seed breeding companies.
The firm said it plans to sign between five and 10 additional biopharma collaborations in fiscal year 2020, some with milestone and royalty payment structures.
Columbia University researchers have adapted a capture-based targeted sequencing method for viral genomes to detect bacteria in clinical samples.
Roche said the layoffs at its Madison, Wisconsin site will start Dec. 31 and continue through June 30, 2020.
At the AGBT conference this week, the DNA synthesis discussed the new capture products and its overall business.
The firm envisions applying its new PlexSet technology to the upper end of multiplex gene expression analysis as well as CRISPR validation applications.
The researchers also applied their database to impute alleles in the region linked to psoriasis.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.